The FDA has announced that it has withdrawn its approval of umbralisib (Ukoniq®, TG Therapeutics) for treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). Umbralisib had previously been granted accelerated approval in February 2021 based on the UNITY-NHL trial (NCT02793583). The withdrawal of this treatment was determined due to updated data from the UNITY-CLL trial (NCT02612311), which revealed a possible increased risk of death in patients receiving umbralisib. TG Therapeuti...

The FDA has granted accelerated approval to zanubrutinib (Brukinsa®, BeiGene) for the treatment of patients with relapsed/refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. "Marginal zone lymphoma is rare and heterogeneous, and it has been difficult to define optimal therapeutic strategies," wrote Stephen Opat, FRACP, FRCPA, MBBS, Director of Clinical Hematology at Monash Health in Australia, and colleagues, in their publication of the initial results...

​The FDA has approved lenalidomide (Revlimid®, Celgene Corporation) in combination with a rituximab product for relapsed/refractory follicular lymphoma (FL) and relapsed/refractory marginal zone lymphoma (MZL). Follicular lymphoma is the most common form of indolent (slow growing) B-cell non-Hodgkin lymphoma (NHL), accounting for around 20% to 30% of all NHL cases. Marginal zone lymphoma, another type of indolent B-cell NHL, comprises approximately 8% of all NHLs. "Current treatment options for ...

This week, the FDA approved lenalidomide (Revlimid®, Celgene Corporation) in combination with a rituximab product for relapsed/refractory follicular lymphoma (FL) and relapsed/refractory marginal zone lymphoma (MZL). In this interview with i3 Health, John P. Leonard, MD, lead author of the AUGMENT trial, on which the approval was based, discusses the approval's importance and shares his advice for physicians treating patients with relapsed/refractory FL or MZL. Can you comment on the significanc...